A citation-based method for searching scientific literature

Elia Aguado-Fraile, Ania Tassinari, Yuko Ishii, Carlie Sigel, Maeve A Lowery, Lipika Goyal, Camelia Gliser, Liewen Jiang, Shuchi S Pandya, Bin Wu, Nabeel Bardeesy, Sung Choe, Vikram Deshpande. Future Oncol 2021
Times Cited: 2







List of co-cited articles
7 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Ghassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, Robin K Kelley, Sam J Lubner, Jorge Adeva, James M Cleary, Daniel V Catenacci, Mitesh J Borad, John Bridgewater,[...]. Lancet Oncol 2020
175
100

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Maeve A Lowery, Howard A Burris, Filip Janku, Rachna T Shroff, James M Cleary, Nilofer S Azad, Lipika Goyal, Elizabeth A Maher, Lia Gore, Antoine Hollebecque,[...]. Lancet Gastroenterol Hepatol 2019
76
100

Second-line chemotherapy in advanced biliary cancer: a systematic review.
A Lamarca, R A Hubner, W David Ryder, J W Valle. Ann Oncol 2014
162
100

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.
Supriya K Saha, Christine A Parachoniak, Krishna S Ghanta, Julien Fitamant, Kenneth N Ross, Mortada S Najem, Sushma Gurumurthy, Esra A Akbay, Daniela Sia, Helena Cornella,[...]. Nature 2014
250
100

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Juan Valle, Harpreet Wasan, Daniel H Palmer, David Cunningham, Alan Anthoney, Anthony Maraveyas, Srinivasan Madhusudan, Tim Iveson, Sharon Hughes, Stephen P Pereira,[...]. N Engl J Med 2010
100

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
Janeta Popovici-Muller, René M Lemieux, Erin Artin, Jeffrey O Saunders, Francesco G Salituro, Jeremy Travins, Giovanni Cianchetta, Zhenwei Cai, Ding Zhou, Dawei Cui,[...]. ACS Med Chem Lett 2018
134
100

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Wei Xu, Hui Yang, Ying Liu, Ying Yang, Ping Wang, Se-Hee Kim, Shinsuke Ito, Chen Yang, Pu Wang, Meng-Tao Xiao,[...]. Cancer Cell 2011
50

Next generation sequencing for biliary tract cancers.
Timothy P DiPeri, Milind M Javle, Funda Meric-Bernstam. Expert Rev Gastroenterol Hepatol 2021
3
50

Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J W Valle, I Borbath, S A Khan, F Huguet, T Gruenberger, D Arnold. Ann Oncol 2016
244
50

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Patrick S Ward, Jay Patel, David R Wise, Omar Abdel-Wahab, Bryson D Bennett, Hilary A Coller, Justin R Cross, Valeria R Fantin, Cyrus V Hedvat, Alexander E Perl,[...]. Cancer Cell 2010
50

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Apinya Jusakul, Ioana Cutcutache, Chern Han Yong, Jing Quan Lim, Mi Ni Huang, Nisha Padmanabhan, Vishwa Nellore, Sarinya Kongpetch, Alvin Wei Tian Ng, Ley Moy Ng,[...]. Cancer Discov 2017
302
50

Epidemiology of Cholangiocarcinoma; United States Incidence and Mortality Trends.
Mohamed M Gad, Anas M Saad, Mohammed Faisaluddin, Mihnea Alexandru Gaman, Inas A Ruhban, Khalid A Jazieh, Muneer J Al-Husseini, Carlos Roberto Simons-Linares, M Bassam Sonbol, Bassam N Estfan. Clin Res Hepatol Gastroenterol 2020
10
50

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
Lipika Goyal, Aparna Govindan, Rahul A Sheth, Valentina Nardi, Lawrence S Blaszkowsky, Jason E Faris, Jeffrey W Clark, David P Ryan, Eunice L Kwak, Jill N Allen,[...]. Oncologist 2015
73
50

Epidemiology of cholangiocarcinoma.
Annika Bergquist, Erik von Seth. Best Pract Res Clin Gastroenterol 2015
197
50

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
John N Primrose, Richard P Fox, Daniel H Palmer, Hassan Z Malik, Raj Prasad, Darius Mirza, Alan Anthony, Pippa Corrie, Stephen Falk, Meg Finch-Jones,[...]. Lancet Oncol 2019
308
50

Pathogenesis, diagnosis, and management of cholangiocarcinoma.
Sumera Rizvi, Gregory J Gores. Gastroenterology 2013
649
50

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
Bin Fan, Ingo K Mellinghoff, Patrick Y Wen, Maeve A Lowery, Lipika Goyal, William D Tap, Shuchi S Pandya, Erika Manyak, Liewen Jiang, Guowen Liu,[...]. Invest New Drugs 2020
37
50

Biliary cancer: Utility of next-generation sequencing for clinical management.
Milind Javle, Tanios Bekaii-Saab, Apurva Jain, Ying Wang, Robin Katie Kelley, Kai Wang, Hyunseon C Kang, Daniel Catenacci, Siraj Ali, Sunil Krishnan,[...]. Cancer 2016
144
50

Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.
Maeve A Lowery, Laura W Goff, Bridget P Keenan, Emmet Jordan, Rui Wang, Andrea G Bocobo, Joanne F Chou, Eileen M O'Reilly, James J Harding, Nancy Kemeny,[...]. Cancer 2019
24
50

Genomic spectra of biliary tract cancer.
Hiromi Nakamura, Yasuhito Arai, Yasushi Totoki, Tomoki Shirota, Asmaa Elzawahry, Mamoru Kato, Natsuko Hama, Fumie Hosoda, Tomoko Urushidate, Shoko Ohashi,[...]. Nat Genet 2015
522
50

Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?
Shahid A Khan, Shireen Emadossadaty, Nimzing G Ladep, Howard C Thomas, Paul Elliott, Simon D Taylor-Robinson, Mireille B Toledano. J Hepatol 2012
179
50

Second-line therapies in advanced biliary tract cancers.
Sri Harsha Tella, Anuhya Kommalapati, Mitesh J Borad, Amit Mahipal. Lancet Oncol 2020
29
50

Liver Transplantation for Cholangiocarcinoma and Mixed Hepatocellular Cholangiocarcinoma: Working Group Report From the ILTS Transplant Oncology Consensus Conference.
Gonzalo Sapisochin, Milind Javle, Jan Lerut, Masayuki Ohtsuka, Mark Ghobrial, Taizo Hibi, Nancy Man Kwan, Julie Heimbach. Transplantation 2020
17
50

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Lenny Dang, David W White, Stefan Gross, Bryson D Bennett, Mark A Bittinger, Edward M Driggers, Valeria R Fantin, Hyun Gyung Jang, Shengfang Jin, Marie C Keenan,[...]. Nature 2009
50

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.
Lukas Bunse, Stefan Pusch, Theresa Bunse, Felix Sahm, Khwab Sanghvi, Mirco Friedrich, Dalia Alansary, Jana K Sonner, Edward Green, Katrin Deumelandt,[...]. Nat Med 2018
137
50

Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.
W R Jarnagin, Y Fong, R P DeMatteo, M Gonen, E C Burke, J Bodniewicz BS, M Youssef BA, D Klimstra, L H Blumgart. Ann Surg 2001
857
50

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
P Wang, Q Dong, C Zhang, P-F Kuan, Y Liu, W R Jeck, J B Andersen, W Jiang, G L Savich, T-X Tan,[...]. Oncogene 2013
247
50

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Sung Choe, Hongfang Wang, Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Gail J Roboz, Jessica K Altman, Alice S Mims, Justin M Watts, Daniel A Pollyea,[...]. Blood Adv 2020
46
50

Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study.
Yasser H Shaib, Hashem B El-Serag, Jessica A Davila, Robert Morgan, Katherine A McGlynn. Gastroenterology 2005
365
50

Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections.
Masato Nagino, Tomoki Ebata, Yukihiro Yokoyama, Tsuyoshi Igami, Gen Sugawara, Yu Takahashi, Yuji Nimura. Ann Surg 2013
348
50

Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.
Michelle L DeOliveira, Steven C Cunningham, John L Cameron, Farin Kamangar, Jordan M Winter, Keith D Lillemoe, Michael A Choti, Charles J Yeo, Richard D Schulick. Ann Surg 2007
791
50

Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.
A Demols, I Borbath, M Van den Eynde, G Houbiers, M Peeters, R Marechal, T Delaunoit, J-C Goemine, S Laurent, S Holbrechts,[...]. Ann Oncol 2020
24
50

Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update.
Shahid A Khan, Brian R Davidson, Robert D Goldin, Nigel Heaton, John Karani, Stephen P Pereira, William M C Rosenberg, Paul Tait, Simon D Taylor-Robinson, Andrew V Thillainayagam,[...]. Gut 2012
472
50

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
Maeve A Lowery, Ryan Ptashkin, Emmet Jordan, Michael F Berger, Ahmet Zehir, Marinela Capanu, Nancy E Kemeny, Eileen M O'Reilly, Imane El-Dika, William R Jarnagin,[...]. Clin Cancer Res 2018
141
50

New Horizons for Precision Medicine in Biliary Tract Cancers.
Juan W Valle, Angela Lamarca, Lipika Goyal, Jorge Barriuso, Andrew X Zhu. Cancer Discov 2017
213
50

Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients.
Dario Ribero, Antonio Daniele Pinna, Alfredo Guglielmi, Antonio Ponti, Gennaro Nuzzo, Stefano Maria Giulini, Luca Aldrighetti, Fulvio Calise, Giorgio Enrico Gerunda, Mariano Tomatis,[...]. Arch Surg 2012
179
50

IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Chao Lu, Patrick S Ward, Gurpreet S Kapoor, Dan Rohle, Sevin Turcan, Omar Abdel-Wahab, Christopher R Edwards, Raya Khanin, Maria E Figueroa, Ari Melnick,[...]. Nature 2012
50



The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
N K Aaronson, S Ahmedzai, B Bergman, M Bullinger, A Cull, N J Duez, A Filiberti, H Flechtner, S B Fleishman, J C de Haes. J Natl Cancer Inst 1993
50

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
50

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
301
50

Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
Jesus M Banales, Jose J G Marin, Angela Lamarca, Pedro M Rodrigues, Shahid A Khan, Lewis R Roberts, Vincenzo Cardinale, Guido Carpino, Jesper B Andersen, Chiara Braconi,[...]. Nat Rev Gastroenterol Hepatol 2020
232
50

Chemotherapy for cholangiocarcinoma: An update.
Natalia Ramírez-Merino, Santiago Ponce Aix, Hernán Cortés-Funes. World J Gastrointest Oncol 2013
94
50

Systemic Therapy of Cholangiocarcinoma.
Ruben R Plentz, Nisar P Malek. Visc Med 2016
13
50

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
50

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew S Paulson, Mitesh J Borad, David Gallinson, Adrian G Murphy,[...]. Lancet Oncol 2020
283
50

Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis.
Florian Moik, Jakob M Riedl, Thomas Winder, Angelika Terbuch, Christopher H Rossmann, Joanna Szkandera, Thomas Bauernhofer, Anne-Katrin Kasparek, Renate Schaberl-Moser, Andreas Reicher,[...]. Sci Rep 2019
10
50

Adjusting overall survival for treatment switches: commonly used methods and practical application.
Claire Watkins, Xin Huang, Nicholas Latimer, Yiyun Tang, Elaine J Wright. Pharm Stat 2013
38
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.